Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 2349-2355, July 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plunkett, W.
Right arrow Articles by Montgomery, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plunkett, W.
Right arrow Articles by Montgomery, J. A.

Comparison of the Toxicity and Metabolism of 9-ß-D-Arabinofuranosyl-2-fluoroadenine and 9-ß-D-Arabinofuranosyladenine in Human Lymphoblastoid Cells1

William Plunkett2, Sherri Chubb, Lillie Alexander and John A. Montgomery

Department of Developmental Therapeutics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030 [W. P., S. C., L. A.], and Organic Chemistry Department, Southern Research Institute, Birmingham, Alabama 35205 [J. A. M.]

The toxicity and metabolism of 9-ß-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), an adenosine deaminase-resistant nucleoside analog, have been compared to those of 9-ß-D-arabinofuranosyladenine (ara-A) in the presence of the adenosine deaminase inhibitor, deoxycoformycin. Equal concentrations of F-ara-A and ara-A plus deoxycoformycin produced similar inhibition of growth of CCRF-CEM human lymphoblastoid cells. 9-ß-D-Arabinofuranosyl-2-fluoroadenine 5'-triphosphate (F-ara-ATP) and 9-ß-D-arabinofuranosyladenine 5'-triphosphate (ara-ATP), were concentratively accumulated intracellularly and exerted their major inhibitory effect on DNA synthesis. Two approaches were used to compare the effect of these nucleotide analogs on the DNA-synthetic capacity of whole cells. (a) The concentrations of F-ara-ATP and ara-ATP in cells incubated with the respective nucleosides were determined directly at the same time that the DNA-synthetic capacity of the cells in each culture was measured by incorporation of [3H]thymidine into DNA. Neither compound significantly affected the specific activity of cellular [3H]deoxythymidine triphosphate. (b) The rates of disappearance of F-ara-ATP and ara-ATP from cells washed free of the nucleosides were determined. These values were used to calculate the cellular concentration of each nucleotide analog in cells in which DNA-synthetic capacity was monitored after incubation with F-ara-A or ara-A plus deoxycoformycin and washed into fresh media. These determinations indicated that the rates of accumulation of F-ara-ATP and ara-ATP differed and were related to the concentration of the exogenous nucleoside. F-ara-ATP disappeared from cells in drug-free media at several times the rate of the disappearance of ara-ATP. However, at equal cellular concentrations, F-ara-ATP was slightly more inhibitory to the processes measured by thymidine incorporation than was ara-ATP. We conclude that F-ara-ATP and ara-ATP share a similar mechanism of action and potency of inhibition of DNA synthesis. The fact that F-ara-A retains its cytotoxic efficacy in the absence of inhibitors of adenosine deaminase provides a rationale for investigating its antitumor properties further.

1 Supported by NIH Grants CA 14528, CA 11520, and RR 05511; Contract N01 CM 87185; and American Cancer Society Grant CH-130.

2 To whom requests for reprints should be addressed.

Received 11/15/79. Accepted 4/ 3/80.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Crul, N. E. Schoemaker, D. Pluim, M. Maliepaard, R. W. M. Underberg, M. Schot, R. W. Sparidans, P. Baas, J. H. Beijnen, N. van Zandwijk, et al.
Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., September 1, 2003; 9(10): 3526 - 3533.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Mansson, T. Spasokoukotskaja, J. Sallstrom, S. Eriksson, and F. Albertioni
Molecular and Biochemical Mechanisms of Fludarabine and Cladribine Resistance in a Human Promyelocytic Cell Line
Cancer Res., December 1, 1999; 59(23): 5956 - 5963.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-i. Kamiya, P. Huang, and W. Plunkett
Inhibition of the 3' right-arrow 5' Exonuclease of Human DNA Polymerase epsilon by Fludarabine-terminated DNA
J. Biol. Chem., August 9, 1996; 271(32): 19428 - 19435.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.